Prognosis in patients with sentinel node-positive melanoma without immediate completion lymph node dissection
Augustinus P. T. van der Ploeg(Erasmus MC Cancer Institute), Alexander M.M. Eggermont(University Medical Center Utrecht), Alessandro Testori(European Organisation for Research and Treatment of Cancer), Omgo E. Nieweg(The University of Sydney), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Alexander C. J. van Akkooi(The University of Sydney), Stefan Suciu(St James's University Hospital), Cornelis Verhoef(Erasmus MC Cancer Institute), Martin Cook(Royal Surrey NHS Foundation Trust), Carlo Riccardo Rossi(University of Padua)
Cited by 49
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
|CA A Cancer Journal for Clinicians|2017|2.3k